Rigel Pharmaceuticals (NASDAQ:RIGL) named Alison L. Hannah as EVP and Chief Medical Officer effective July 1, 2026, as the company advances a Phase 1b trial of R289 in relapsed/refractory lower‑risk MDS with dose escalation and Phase 2 dosing set for H2 2026 and preliminary expansion data due by end‑2026.
Previous Week Recap
- Rigel Appoints CMO: Rigel Pharmaceuticals (RIGL) appointed Alison L. Hannah as EVP and Chief Medical Officer effective July 1, 2026; Lisa Rojkjaer no longer serves in that role.
- Rigel Trs R289 Trial: Rigel (RIGL) runs a Phase 1b trial of R289 in relapsed/refractory lower‑risk MDS. Enrollment and recommended Phase 2 dose expected H2 2026; preliminary dose‑expansion data due by end‑2026.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.